Premium
Increased expression of MUC ‐1 has close relation with patient survivor in high‐grade salivary gland mucoepidermoid carcinoma
Author(s) -
Siyi Li,
Shengwen Liu,
Min Ruan,
Wenjun Yang,
Lizheng Wang,
Chenping Zhang
Publication year - 2014
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12170
Subject(s) - mucoepidermoid carcinoma , medicine , immunohistochemistry , salivary gland , submandibular gland , stage (stratigraphy) , pathology , carcinoma , metastasis , gastroenterology , oncology , cancer , biology , paleontology
Purpose High‐grade mucoepidermoid carcinoma ( MEC ) is an infrequent malignant neoplasm originates most commonly in the salivary glands with poor prognosis. Thus far, there is little knowledge on MUC ‐1 expression in high‐grade MEC or how it may relate to patient survival. The aim of this study was to determine the extent of MUC ‐1 expression in high‐grade MEC and correlate expression with clinic outcome. Methods Surgical specimens from 62 cases of primary high‐grade MEC and 10 cases of normal salivary gland tissue were examined by immunohistochemistry. The relationship between MUC ‐1 expression and the clinicopathological data and patient survival was analyzed. Results The disease‐free survival rates were 54.6% (3 years) and 37.7% (5 years) for high‐grade MEC patients. Patient who with primary location at submandibular gland have the worst prognosis ( P = 0.042) in comparing with other sites. High expression of MUC ‐1 in high‐grade MEC was significantly correlated with lymphatic/regional metastasis ( P = 0.003) and clinic stage ( P = 0.02), and high expression of MUC ‐1 (>75%) was confirmed to be significant independent prognostic factors in high‐grade MEC patients [ HR 2.929 (95% CI 1.246–6.881); P < 0.0137]. Conclusions The findings suggest that high levels of MUC ‐1 expression may be a potential marker for worse outcome in high‐grade MEC and could be used as a new molecule target to improve outcomes for these patients in the future.